Note: Descriptions are shown in the official language in which they were submitted.
CA 02467462 2004-05-25
612178 WO
1
METERED DOSE INHALER FOR SALMETEROL
BACKGROUND OF THE INVENTION
This application is a division of Canadian application
Serial No. 2,217,954, filed April 10, 1996.
Drugs for treating respiratory and nasal disorders are frequently administered
in
aerosol formulations through the mouth or nose. One widely used method for
dispensing such aerosol drug formulations involves making a suspension
formulation of the drug as a finely divided powder in a liquefied gas known as
a
propellant. The suspension is stored in a sealed container capable of
withstanding the pressure required to maintain the propellant as a liquid. The
suspension is dispersed by activation of a dose metering valve affixed to the
container.
A metering valve may be designed to consistently release a fixed,
predetermined
mass of the drug formulation upon each activation. As the suspension is forced
from the container through the dose metering valve by the high vapor pressure
of
the propellant, the propellant rapidly vaporizes leaving a fast moving cloud
of very
fine particles of the drug formulation. This cloud of particles is directed
into the
nose or mouth of the patient by a channelling device such as a cylinder or
open-
ended cone. Concurrently with the activation of the aerosol dose metering
valve,
the patient inhales the drug particles into the lungs or nasal cavity. Systems
of
dispensing drugs in this way are known as 'metered dose inhalers' (MDI's). See
Peter Byron, Respiratory Drug Delivery, CRC Press, Boca Raton, FL (1990) for a
general background on this form of therapy.
Patients often rely on medication delivered by MDI's for rapid treatment of
respiratory disorders which are debilitating and in some cases, even life
threatening. Therefore, it is essential that the prescribed dose of aerosol
medication delivered to the patient consistently meet the specifications
claimed by
the manufacturer and comply with the requirements of the FDA and other
regulatory authorities. That is, every dose in the can must be the same within
close tolerances.
CA 02467462 2004-05-25
G1217s wo
2
Some aerosol drugs tend to adhere to the inner surfaces, i.e., walls of the
can,
valves, and caps, of the MDI. This can lead to the patient getting
significantly less
than the prescribed amount of drug upon each activation of the MDI. The
problem
is particularly acute with hydrofluoroalkane {also known as simply
"fluorocarbon")
propellant systems, e.g., P134a and P227, under development in recent years to
replace chlorofluorocarbons such as P11, P114 and P12.
We have found that coating the interior can surfaces of MDI's with a
fluorocarbon
polymer significantly reduces or essentially eliminates the problem of
adhesion or
deposition of salmeterol on the can walls and thus ensures consistent delivery
of
medication in aerosol from the MDI.
SUMMARY OF THE INVENTION
A metered dose inhaler having part or all of its internal surfaces coated with
one
or more fluorocarbon polymers, in combination with one or more non-
fluorocarbon polymers, for dispensing an inhalation drug formulation
comprising
salmeterol, or a physiologically acceptable salt thereof, and a fluorocarbon
propellant, optionally in combination with one or more other pharmacologically
active agents or one or more ~excipients.
CA 02467462 2004-05-25
In accordance with one aspect of the invention, there is provided an
inhalation
pharmaceutical preparation comprising an inhalation drug formulation which
comprises salmeterol or a physiologically acceptable salt thereof and a
fluorocarbon propellant in a metered dose inhaler having pan or all of its
internal
surfaces coated with a polymer blend comprising one or more fluorocarbon
polymers in combination with one or more non-fluorocarbon polymers.
In accordance with another aspect of the invention, there is provided use of
an
inhalation drug formulation comprising salmeterol or a physiologically
acceptable
salt thereof and a fluorocarbon propellant for the treatment of respiratory
and nasal
l0 disorders, the formulation being dispensed in a metered dose inhaler having
part or
all of its internal surfaces coated with a polymer blend comprising one or
more
fluorocarbon polymers in combination with one or more non-fluorocarbon
polymers.
DETAILED DESCRIPTION OF THE INVENTION
The term "metered dose inhaler" or "MDI" means a unit comprising a can, a
crimped cap covering the mouth of the can, and a drug metering valve situated
in
the cap , while the term "MDI system" also includes a suitable channelling
device.
The terms "MDI can" means the container without the cap and valve. The term
"drug metering valve" or "MDI valve" refers to a valve and its associated
2o mechanisms which delivers a predetermined amount of drug formulation from
an
MDI upon each activation. The channelling device may comprise, for example, an
actuating device for the valve and a cylindrical or cone-like passage through
which
medicament may be delivered from the filled MDI can via the MDI valve to the
nose or mouth of a patient, e.g. a mouthpiece actuator. The relation of the
parts
CA 02467462 2004-05-25
612178 WO
4
of a typical MDI is illustrated in US Patent 5,261,538:
The term "fluorocarbon polymers" means a polymer in which one or more of the
hydrogen atoms of the hydrocarbon chain have been replaced by fluorine atoms.
Thus, "fluorocarbon polymers" include perfluorocarbon, hydrofluorocarbon,
chlorofluorocarbon, hydro-chlorofluorocarbon polymers or other halogen
substituted derivatives thereof. The "fluorocarbon polymers" may be branched,
homo-polymers or co-polymers.
U.S. Patent No.4,992,474, teaches a
bronchodilating compound particularly useful in the treatment of asthma and
other
respiratory diseases know by the chemical name 4-hydroxy-a'-[[[6-(4-
phenylbutoxy)hexyl]amino]methyl]-1,3-benzenedimethanol and the generic name
'salmeterol'. Salmeterol as the free base and as acid addition salts
(particularly
as the 1-hydroxy-2-naphthalenecarboxylic acid salt also known as
hydroxynaphthoate or xinafoate salt), especially in aerosol form, has been
accepted by the medical community as a useful treatment of asthma and is
marketed under the trademark 'Serevent'
The term 'drug formulation' means salmeterol or a physiologically acceptable
salt
thereof (particularly the hydroxynaphthoate salt) optionally in combination
with one
or more other pharmacologically active agents such as antiinflammatory agents,
analgesic agents or other respiratory drugs and optionally containing one or
more
excipients. The term "excipients" as used herein mean chemical agents having
little or no pharmacological activity (for the quantities used) but which
enhance the
drug formulation or the performance of the MDl system. For example, excipients
include but are not limited to surfactants, preservatives, flavorings,
antioxidants,
antiaggregating agents, and cosolvents, e.g., ethanol and diethyl ether.
Salmeterol or salt thereof may be used in the fom~ of its R-isomer.
Suitable surfactants are generally known in the art, for example,
those surfactants disclosed in European Patent Specification
No: 0327777, published 1608:89: The amount of surfactant
CA 02467462 2004-05-25
612178 WO
employed is desirable in the range of 0.0001 % to 50°!° weight
to weight ratio
relative to the drug, in particular, 0.05 to 5°I° weight to
weight ratio. A particularly
useful surfactant is 1,2-di[7-(F-hexyl) hexanoyl]- glycero-3-phospho-N,N,N-
trimethylethanolamine also know as 3, 5, 9-trioxa-4-phosphadocosan-1-aminium,
5 i 7, 17, 18, 18, 19, 19, 20, 20, 21, 21, 22, 22, 22-tridecafluoro-7-[(8, 8,
9, 9, 10, 10,
11, 11, 12, 12, 13, 13, 13-tridecafluoro-1-oxotridecyl)oxy]-4-hydroxy-N, N, N-
trimethyl-10-oxo-, inner salt, 4-oxide.
A polar cosolvent such as CZ.6 aliphatic alcohols and polyols e.g. ethanol,
isopropanol and propylene glycol, preferably ethanol may be included in the
drug
formulation in the desired amount, either as the only excipient or in addition
to
other excipients such as surfactants. Suitably, the drug formulation may
contain
0.01 to 5% wlw based on the propellant of a polar cosolvent e.g. ethanol,
preferably 0.1 to 5°!° wlw e.g. about 0.1 to 1 % wlw.
It will be appreciated by those skilled in the art that the drug formulation
for use in
the invention may, if desired, contain salmeterol or a salt thereof in
combination
with one or more other pharmacologically active agents. Such medicaments may
be selected from any suitable drug useful in inhalation therapy. Appropriate
medicaments may thus be selected from, for example, analgesics, e.g. codeine,
dihydromorphine, ergotarnine, fentanyl or morphine; anginal preparations, e.g.
diltiazem; antiallergics, e.g. cromoglycate, ketotifen or nedocromil;
antiinfectives
e.g. cephalosporins, penicillins, streptomycin, sulphonamides, tetracyclines
and
pentamidine; antihistamines, e.g. methapyrilene; anti-inflammatories, e.g.
beclomethasone (e.g. the dipropionate}, flunisolide, budesonide, tipredane or
triamcinolone acetonide; antitussives, e.g. noscapine; bronchodilators, e.g.
salbutamol, ephedrine, adrenaline, fenoterol, formoterol, isoprenatine,
metaproterenol, phenylephrine, phenylpropanolamine, pirbuterol, reproterol,
rimiterol, terbutaline, isoetharine, tulobuterol, orciprenaline, or (-}-4-
amino-3,5-
d i c h I o ro- a -[[[6-[2-(2-
pyridinyl)ethoxy]hexyl]amino]methyl]benzenemethanol;
diuretics, e.g. amiloride; anticholinergics e.g. ipratropium, atropine or
oxitropium;
hormones, e.g. cortisone, hydrocortisone or prednisolone; xanthines e.g.
aminophylline, choline theophyllinate, lysine theophyllinate or theophylline;
and
CA 02467462 2004-05-25
612178 WO
6
therapeutic proteins and peptides, e.g. insulin or glucagon. It will be clear
to a
person skilled in the art that, where appropriate, the medicaments may be used
in
the form of salts (e.g. as alkali metal or amine salts or as acid addition
salts) or as
esters (e.g. lower alkyl esters) or as solvates (e.g. hydrates) to optimise
the
activity and/or stability of the medicament andJor to minimise the solubility
of the
medicament in the propellant.
Particularly preferred drug formulations contain salmeterol or a
physiologically
acceptable salt thereof in combination with an anti-inflammatory steroid such
as
fluticasone propionate, beclomethasone dipropionate or physiologically
acceptable solvates thereof.
A particularly preferred drug combination is safmeterol xinafoate and
fluticasone
propionate.
'Propellants" used herein mean pharmacologically inert liquids with boiling
points
from about room temperature (25°C) to about -25°C which singly
or in combination
exert a high vapor pressure at room temperature. Upon activation of the MDI
system, the high vapor pressure of the propellant in the MDI forces a metered
amount of drug formulation out through the metering valve then the propellant
very rapidly vaporizes dispersing the drug particles. The propellants used in
the
present invention are low boiling fluorocarbons; in particular, 1,1,1,2-
tetrafluoroethane also known as "propellant 134a" or 'P 134a" and 1, i
,1,2,3,3,3-
heptafluoro-n-propane also known as 'propellant 227" or "P 227'.
Drug formulations for use in the invention may be free or substantially free
of
formulation excipients e.g. surfactants and cosolvents etc. Such drug
formulations are advantageous since they may be substantially taste and odour
free, less irritant and less toxic than excipient-containing formulations.
Thus, a
preferred drug formulation consists essentially of salmeterol or a
physiologically
acceptable salt thereof, e.g. the xinafoate salt, optionally in combination
with one
or more other pharmacologically active agents particularly fluticasone
propionate
{or a physiologically acceptable solvate thereof), and a fluorocarbon
propellant.
CA 02467462 2004-05-25
612178 WO
Preferred propellants are 1,1,1,2-tetrafiuoroethane, 1,1,1,2,3,3,3-heptafluoro-
n-
propane or mixtures thereof, and especially 1,1,1,2-tetrafluoroethane.
Further drug formulations for use in the invention may be free or
substantially free
of surfactant. Thus, a further preferred drug formulation comprises or
consists
e~g~-sat'ly c~ sad {or a physiologically acceptable salt thereof), optionally
in
combination with one or more other pharmacologically active agents, a
fluorocarbon propellant and 0.01 to 5% w/w based upon propellant of a polar
cosolvent, which formulation is substantially free of surfactant. Preferred
propellants are 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoro-n-propane
or
mixtures thereof, and especially 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-
heptafluoro-n-propane.
Most often the MDI can and cap are made of aluminum or an alloy of aluminum,
although other metals not affected by the drug formulation, such as stainless
steel
an alloy of copper, or tin plate, may be used. An MDI can may also be
fabricated
from glass or plastic. Preferably, however, the MDI cans employed in the
present
invention are made of aluminium or an alloy thereof. Advantageously,
strengthened aluminium or aluminum alloy MDI cans may be employed. Such
strengthened MDI cans are capable of withstanding particularly stressful
coating
and curing conditions, e.g. particularly high temperatures, which may be
required
for certain fluorocarbon polymers. Strengthened MDI cans which have a reduced
tendency to malform under high temperatures include MDI cans comprising side
walls and a base of increased thickness and MDI cans comprising a
substantially
ellipsoidal base (which increases the angle between the side walls and the
base
of the can), rather than the hemispherical base of standard MDI cans. MDI cans
having an ellipsoidal base offer the further advantage of facilitating the
coating
process.
The drug metering valve consists of parts usually made of stainless steel, a
pharmacologically inert and propellant resistant polymer, such as acetal,
polyamide {e.g., Nylon~), polycarbonate, polyester, fluorocarbon polymer
{e.g.,
Teflono) or a combination of these materials. Additionally, seals and "O"
rings of
CA 02467462 2004-05-25
612178 WO
8
various materials (e.g., nitrite rubbers, polyurethane, acetyl resin,
fluorocarbon
polymers), or other elastomeric materials are employed in and around the
valve.
Fluorocarbon polymers for use in the invention include fluorocarbon polymers
which are made of multiples of one or more of the following monomeric units:
tetrafluoroethylene (PTFE), fluorinated ethylene propylene (FEP),
perfluoroalkoxyalkane (PFA), ethylene tetrafluoroethylene (ETFE),
vinyldieneffuoride (PVDF), and chlorinated ethylene tetrafluoroethylene.
Fluorinated polymers which have a relatively high ratio of fluorine to carbon,
such
as perfluorocarbon polymers e.g. PTFE, PFA, and FEP, are preferred.
The fluorinated polymer may be blended with non-fluorinated polymers such as
polyamides, polyimides, polyethersulfones, polyphenylene sulfides and amine-
formaldehyde thermosetting resins. These added polymers improve adhesion of
the polymer coating to the can walls. Preferred polymer blends are
PTFE/FEPlpolyamideimide, PTFElpolyethersulphone (PES) and FEP-
benzoguanamine.
Particularly preferred coatings are pure PFA, FEP and blends of PTFE and
polyethersulphone (PES).
Fluorocarbon polymers are marketed under trademarks such as Teflon~, Tefzel~,
Halar~, Hostaflon~, Polyflon~ and Neoflon~. Grades of polymer include FEP
DuPont 856-200, PFA DuPont 857-200, PTFE-PES DuPont 3200-100, PTFE-
FEP-polyamideimide DuPont 856P23485, FEP powder DuPont 532, and PFA
Hoechst 6900n. The coating thickness is in the range of about 1 um to about
1 mm. Suitably the coating thickness is in the range of about 1 pm to about
100pm,
e.g. lp.m to 25~.m. Coatings may be applied in one or more coats.
Preferably the fluorocarbon polymers for use in the invention are coated on to
MDI
cans made of metal, especially MDI cans made of aluminium or an alloy thereof.
CA 02467462 2004-05-25
612178 WO
9
The particle size of the particular (e.g., micronised) drug should be such as
to
permit inhalation of substantially all the drug into the lungs upon
administration of
the aerosol formulation and will thus be less than 100 microns, desirably less
than
20 microns, and preferably in the range of 1-10 microns, e.g., 1-5 microns.
The final aerosol formulation desirably contains 0.005-10°l°
weight to weight ratio,
in particular 0.005-5°I° weight to weight ratio, especially 0.01-
1.0°1° weight to
weight ratio, of drug relative to the total weight of the formulation.
A further aspect of the present invention is a metered dose inhaler having
part or
all of its internal metallic surfaces coated with one or more fluorocarbon
polymers,
optionally in combination with one or more non-fluorocarbon polymers, for
dispersing an inhalation drug formulation comprising salmeterol or a salt
thereof
and a fluorocarbon propellant optionally in combination with one or more other
pharmacologically active agents and one or more excipients.
A particular aspect of the present invention is an MDI having part or
essentially all
of its internal metallic surfaces coated with PFA or FEP, or blended
fluoropolymer
resin systems such as PTFE-PES with or without a primer coat of a
polyamideimide or polyethersulfone for dispensing a drug formulation as
defined
hereinabove. Preferred drug formulations for use in this MDI consist
essentially of
salmeterol (or a salt thereof, e.g. the xinafoate salt), optionally in
combination with
one or more other pharmacologically active agents particularly fluticasone
propionate or a physiologically acceptable solvate thereof and a fluorocarbon
propellant, particularly 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoro-
n-
propane or mixtures thereof, and especially 1,1,1,2-tetrafluoroethane.
Preferably
the MDI can is made of aluminium or an alloy thereof.
The MDI can may be coated by the means known in the art of metal coating. For
example, a metal, such as aluminum or stainless steel, may be precoated as
coil
stock and cured before being stamped or drawn into the can shape. This method
is well suited to high volume production for two reasons. First, the art of
coating
coil stock is well developed and several manufacturers can custom coat metal
coil
CA 02467462 2004-05-25
612178 WO
to
stock to high standards of uniformity and in a wide range of thicknesses.
Second,
the precoated stock can be stamped or drawn at high speeds and precision by
essentially the same methods used to draw or stamp uncoated stock.
Other techniques for obtaining coated cans is by electrostatic dry powdered
coating or by spraying preformed MDI cans inside with formulations of the
coating
fluorinated polymer/polymer blend and then curing. The preformed MDI cans may
also be dipped in the fluorocarbon polymer/polymer blend coating formulation
and
cured, thus becoming coated on the inside and out.. The fluorocarbon
polymer/polymer blend formulation may also be poured inside the MDI cans then
drained out leaving the insides with the polymer coat. Conveniently, for ease
of
manufacture, preformed MDI cans are spray-coated with the fluorinated
polymer/polymer blend.
The fluorocarbon polymer/polymer blend may also be formed in situ at the can
walls using plasma polymerization of the fluorocarbon monomers. Fluorocarbon
polymer film may be blown inside the MDI cans to form bags. A variety of
fluorocarbon polymers such as ETFE, FEP, and PTFE are available as film stock.
The appropriate curing temperature is dependent on the fluorocarbon
polymer/polymer blend chosen for the coating and the coating method employed.
However, for coil coating and spray coating temperatures in excess of the
melting
point of the polymer are typically required, for example, about 50°C
above the
melting point for up to about 20 minutes such as about 5 to 10 minutes e.g.
about
8 minutes or as required. For the above named preferred and particularly
preferred fluorocarbon polymer/polymer blends curing temperatures in the range
of about 300°C to about 400°C, e.g. about 350°C to
380°C are suitable. For
plasma polymerization typically temperatures in the range of about 20°C
to about
100°C may be employed.
The MDI's taught herein may be prepared by methods of the art (e.g., see
8yron,
above and U.S. patent 5,345,980) substituting conventional cans for those
coated
with a fluorinated polymerlpolymer blend. That is, salmeterol or a salt
thereof and
CA 02467462 2004-05-25
612178 WO
11
other components of the formulation are filled into an aerosol can coated with
a
fluorinated polymerlpolymer blend. The can is fitted with a cap assembly which
is
crimped in place. The suspension of the drug in the fluorocarbon propellant in
liquid form may be introduced through the metering valve as taught in U.S.
5,345,980_
The MDI's with fluorocarbon polymerlpolymer blend coated interiors taught
herein
may be used in medical practice in a similar manner as non-coated MDI's now in
clinical use. However the MDI's taught herein are particularly useful for
containing
and dispensing inhaled drug formulations with hydrofluoroalkane fluorocarbon
propellants such as 134a with little, or essentially no, excipient and which
tend to
deposit or cling to the interior walls and parts of the MDI system. In certain
cases
it is advantageous to dispense an inhalation drug with essentially no
excipient,
e.g., where the patient may be allergic to an excipient or the drug reacts
with an
excipient.
MDI's containing the formulations described hereinabove, MDI systems and the
use of such MDI systems for the treatment of respiratory disorders e.g. asthma
comprise further aspects of the present invention.
It will be apparent to those skilled in the art that modifications to the
invention
described herein can readily be made without departing from the spirit of the
invention. Protection is sought for all the subject matter described herein
including any such modifications.
The following non-limitative Examples serve to illustrate the invention.
EXAMPLES
Example 1
Standard 12.5 ml MDI cans (Presspart Inc., Cart', NC} were spray-coated
(Livingstone Coatings, Charlotte, NC) with primer {DuPont 851-204) and cured
to
CA 02467462 2004-05-25
612178 WO
~2
the vendor's standard procedure, then further spray-coated with either FEP or
PFA (DuPont 856-200 and 857-200, respectively) and cured according to the
vendor's standard procedure. The thickness of the coating is approximately 10
mm to 50 mm. These cans are then purged of air (see PCT application number
W094/22722 (PCTIEP94100921 )), the valves crimped in place, and a suspension
of about 4 mg salmeterol xinafoate (hydroxynaphthoate) in about 12 gm P134a is
filled through the valve.
Exam Ip a 2
Standard 0.46 mm thick aluminum sheet {United Aluminum) was spray-coated
(DuPont, Wilmington, DE) with FEP (DuPont 856-200) and cured. This sheet was
then deep- drawn into cans (Presspart Inc., Cary, NC). These cans were then
purged of air, the valves crimped in place, and a suspension of about 2.5 mg
salmeterol xinafoate (hydroxynaphthoate) in about 7.5 gm P 134A was filled
through the valve.
Exam I
Standard 12.5 ml MDI cans {Presspart Inc., Cary, NC) are spray-coated with
PTFE-PES blend (DuPont) as a single coat and cured according to the vendor's
standard procedure. The thickness of the coating is between approximately 1 um
and approximately 20 Vim. These cans are then purged of air, the valves
crimped
in place, and a suspension of about 6.1 mg of micronised salmeterol xinafoate
in
about 12 g P134a is filled through the valve.
x m f 4
Standard 12.5 ml MDI cans (Presspart Inc., Cary, NC) are spray-coated with
PTFE-FEP-polyamideimide blend {DuPont) and cured according to the vendor's
standard procedure. The thickness of the coating is between approximately 1
fun
and approximately 20 p.m. These cans are then purged of air the valves crimped
in
CA 02467462 2004-05-25
612178 WO
13
place, and a suspension of about 6.1 mg of micronised salmeterol xinafoate in
about 12 g P134a is filled through the valve.
Standard 12.5 ml MDI cans (Presspart Inc., Cary, NC) are spray-coated with FEP
powder (DuPont FEP 532) using an electrostatic gun. The thickness of the
coating
is between approximately 1 ~.m and approximately 20 ~,m. These cans are then
purged of air, the valves crimped in place, and a suspension of about 6.1 mg
of
micronised salmeterol xinafoate in about 12 g P134a is filled through the
valve.
Example 6
Standard 0.46 mm thick aluminium sheet (United Aluminium) is spray coated with
FEP-Benzoguanamine and cured. This sheet is then deep-drawn into cans.
These cans are then purged of air, the valves crimped in place, and a
suspension
of about 6.1 mg of micronised salmeterol xinafoate in about 12 g P134a is
filled
through the valve.
Example 7
Standard 12.5 ml MD1 cans {Presspart Inc., Cary, NC) are spray-coated with an
aqueous dispersion of PFA (Hoechst PFA-6900n) and cured. The thickness of the
coating is between approximately 1 dun and approximately 20 p.m. These cans
are
then purged of air, the valves crimped in place, and a suspension of about 6.1
mg
of micronised salmeterol xinafoate in about 12 g respectively P134a is filled
through the valve.
exam l~e 8
Standard 12.5 ml MDI cans (Presspart Inc., Cary, NC} are spray-coated with
PTFE-PES blend (DuPont) as a single coat and cured according to the vendor's
standard procedure. The thickness of the coating is between approximately 1
~.un
CA 02467462 2004-05-25
612178 WO
14
and approximately 20 p.m. These cans are then purged of air, the valves
crimped
in place, and a suspension of about 4.25 mg of micronised salmeterol xinafoate
in
about 8 g P134a is filled through the valve.
ExarBple 9
Standard 12.5 ml MDI cans (Presspart Inc., Cary, NC) are spray-coated with
PTFE-FEP-polyamideimide blend (DuPont) and cured according to the vendor's
standard procedure. The thickness of the coating is between approximately 1 Nm
and approximately 20 Nm. These cans are then purged of air the valves crimped
in
place, and a suspension of about 4.25 mg of micronised salmeterol xinafoate in
about 8 g P134a is filled through the valve.
Examhe 10
Standard 12.5 ml MDI cans (Presspart Inc., Cary, NC) are spray-coated with FEP
powder (DuPont FEP 532) using an electrostatic gun. The thickness of the
coating
is between approximately 1 p.m and approximately 20 p.m. These cans are then
purged of air, the valves crimped in place, and a suspension of about 4.25 mg
of
micronised salmeterol xinafoate in about 8 g P134a is filled through the
valve.
~x r~ple 11
Standard 0.46 mm thick aluminium sheet (United Aluminium} is spray coated with
FEP-Benzoguanamine and cured. This sheet is then deep-drawn into cans.
These cans are then purged of air, the valves crimped in place, and a
suspension
of about 4.25 mg of micronised salmeterol xinafoate in about 8 g P134a is
filled
through the valve.
~c~mple 12
Standard 12.5 ml MDI cans (Presspart Inc., Cary, NC) are spray-coated with an
aqueous dispersion of PFA (Hoechst PFA-6900n} and cured. The thickness of the
CA 02467462 2004-05-25
612178 WO
coating is between approximately 1 ~m and approximately 20 p.m. These cans are
then purged of air, the valves crimped in place, and a suspension of about
4.25
mg of micronised salmeterol xinafoate in about 8 g P134a is filled through the
valve.
5
Standard 12.5 ml MDI cans (Presspart Inc., Cary, NC) are spray-coated with
PTFE-PES blend (DuPont) as a single coat and cured according to the vendor's
10 standard procedure. The thickness of the coating is between approximately 1
pm
and approximately 20 pm. These cans are then purged of air, the valves crimped
in place, and a suspension of about 6.4 mg micronised salmeterol xinafoate
with
about 8.8 mg, 22 mg or 44 mg micronised fluticasone propionate in about 12 g
P134a is filled through the valve.
Exam Ip a 14
Standard 12.5 ml MDI cans (Presspart Inc., Cary, NC) are spray-coated with
PTFE-FEP-polyamideimide blend (DuPont) and cured according to the vendor's
standard procedure. The thickness of the coating is between approximately 1 pm
and approximately 20 N.m. These cans are then purged of air the valves crimped
in
place, and a suspension of about 6.4 mg micronised salmeterol xinafoate with
about 8.8 mg, 22 mg or 44 mg micronised fluticasone propionate in about 12 g
P134a is filled through the valve.
~xa m I,
Standard 12.5 ml MDI cans (Presspart Inc., Cary, NC) are spray-coated with FEP
powder (DuPont FEP 532) using an electrostatic gun. The thickness of the
coating
is between approximately 1 p.m and approximately 20 pm. These cans are then
purged of air, the valves crimped in place, and a suspension of about 6.4 mg
micronised salmeterol xinafoate with about 8.8 mg, 22 mg or 44 mg micronised
ffuticasone propionate in about 12 g P134a is filled through the valve.
CA 02467462 2004-05-25
612178 WO
16
Standard 0.46 mm thick aluminium sheet (United Aluminium) is spray coated with
FEP-Benzoguanamine and cured. This sheet is then deep-drawn into cans.
These cans are then purged of air, the valves crimped in place, and a
suspension
of about 6.4 mg micronised salmeterol xinafoate with about 8.8 mg, 22 mg or 44
mg micronised fluticasone propionate in about 12 g P134a is filled through the
valve.
Examlhe 1717
Standard 12.5 ml MDI cans (Presspart Inc., Cary, NC) are spray-coated with an
aqueous dispersion of PFA (Hoechst PFA-6900n} and cured. The thickness of the
coating is between approximately 1 p.m and approximately 20 pm. These cans are
then purged of air, the valves crimped in place, and a suspension of about 6.4
mg
micronised salmeterol xinafoate with about 8.8 mg, 22 mg or 44 mg micronised
fluticasone propionate in about 12 g P134a is filled through the valve.
~~c~mple 18
Standard 12.5 ml MDI cans (Presspart Inc., Cary, NC) are spray-coated with
PTFE-PES blend (DuPont) as a single coat and cured according to the vendor's
standard procedure. The thickness of the coating is between approximately 1 Nm
and approximately 20 ~.m. These cans are then purged of air, the valves
crimped
in place, and a suspension of about 4 mg micronised salmeterol xinafoate with
about 5.5 mg, 13.8 mg or 27.5 mg fluticasone propionate in about 8 g P 134a is
filled through the valve.
Example 19
Standard 12.5 ml MDI cans (Presspart Inc., Cary, NC) are spray-coated with
PTFE-FEP-polyarnideimide blend (DuPont) and cured according to the vendor's
CA 02467462 2004-05-25
612178 WO
17
standard procedure. The thickness of the coating is between approximately 1
fun
and approximately 20 pm. These cans are then purged of air the valves crimped
in
place, and a suspension of about 4 mg micronised salmeterol xinafoate with
about 5.5 mg, 13.8 mg or 27.5 mg fluticasone propionate in about 8 g P134a is
filled through the valve.
~xam~e 2Q
Standard 12.5 ml MDI cans (Presspart Inc., Cary, NC) are spray-coated with FEP
powder (DuPont FEP 532) using an electrostatic gun. The thickness of the
coating
is between approximately 1 pm and approximately 20 pm. These cans are then
purged of air, the valves crimped in place, and a suspension of about 4 mg
micronised salmeterol xinafoate with about 5.5 mg, 13.8 mg or 27.5 mg
fluticasone
propionate in about 8 g P134a is filled through the valve.
example 21
Standard 0.46 mm thick aluminium sheet (United Aluminium) is spray coated with
FEP-Benzoguanamine and cured. This sheet is then deep-drawn into cans.
These cans are then purged of air, the valves crimped in place, and a
suspension
of about 4 mg micronised salmeterol xinafoate with about 5.5 mg, 13.8 mg or
27.5
mg fluticasone propionate in about 8 g P134a is filled through the valve.
Standard 12.5 ml MDI cans (Presspart Inc., Cary, NC) are spray-coated with an
aqueous dispersion of PFA (Hoechst PFA-6900n) and cured. The thickness of the
coating is between approximately 1 pm and approximately 20 pm. These cans are
then purged of air, the valves crimped in place, and a suspension of about 4
mg
micronised salmeterol xinafoate with about 5.5 mg, 13.8 mg or 27.5 mg
fluticasone
propionate in about 6 g P134a is filled through the valve.
CA 02467462 2004-05-25
612178 WO
18
F_xam~les 2$-28
Examples 3 to 7 are repeated except that a suspension of about 9.6 mg
micronised
salmeterol xinafoate in about 21.4 g P227 is filled through the valve.
Examples 3 to 7 are repeated except that about 9.6 mg micronised salmeterol
xinafoate in about 182 mg ethanol and about 18.2 g P134a is filled through the
valve.
Exam~~les 34 - 64
Examples 3 to 33 are repeated except that modified 12.5 ml MDI cans (Presspart
Inc. Cary, NC) with an ellipsoid base are used.
Dose delivery from the MDIs tested under simulated use conditions is found to
be
constant, compared to control MDIs filled into uncoated cans which exhibit a
significant decrease in dose delivered through use.
